Literature DB >> 3462743

Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.

I Hellström, P L Beaumier, K E Hellström.   

Abstract

Mouse monoclonal antibody L6 (IgG2a subtype) recognizes a ganglioside antigen expressed at the surface of cells from human non-small-cell lung carcinomas, breast carcinomas, and colon carcinomas. We now show that this antibody can lyse L6 antigen-positive human tumor cells in the presence of Leu-11b-positive human lymphocytes (i.e., mediate antibody-dependent cellular cytotoxicity) or human serum (mediate complement-dependent cytotoxicity) and that it can inhibit the outgrowth of an L6 antigen-positive human tumor transplanted onto nude mice.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3462743      PMCID： PMC386652          DOI： 10.1073/pnas.83.18.7059

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  9 in total

1.  Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies.

Authors:  P L Beaumier; D Neuzil; H M Yang; E A Noll; R Kishore; J F Eary; K A Krohn; W B Nelp; K E Hellström; I Hellström
Journal:  J Nucl Med       Date:  1986-06       Impact factor: 10.057

2.  Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50.

Authors:  P J Martin; G Longton; J A Ledbetter; W Newman; M P Braun; P G Beatty; J A Hansen
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

3.  Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours.

Authors:  H F Sears; B Atkinson; J Mattis; C Ernst; D Herlyn; Z Steplewski; P Häyry; H Koprowski
Journal:  Lancet       Date:  1982-04-03       Impact factor: 79.321

4.  Lymphocyte-dependent antibodies to antigen 3.1, a cell-surface antigen expressed by a subgroup of human melanomas.

Authors:  I Hellström; K E Hellström; M Y Yeh
Journal:  Int J Cancer       Date:  1981-03-15       Impact factor: 7.396

5.  Monoclonal mouse antibodies raised against human lung carcinoma.

Authors:  I Hellström; D Horn; P Linsley; J P Brown; V Brankovan; K E Hellström
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

6.  Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas.

Authors:  H J Garrigues; W Tilgen; I Hellstróm; W Franke; K E Hellström
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

7.  Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?

Authors:  H Koprowski; D Herlyn; M Lubeck; E DeFreitas; H F Sears
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

8.  Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.

Authors:  I Hellström; V Brankovan; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

Authors:  A N Houghton; D Mintzer; C Cordon-Cardo; S Welt; B Fliegel; S Vadhan; E Carswell; M R Melamed; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205
  9 in total
  19 in total

1.  The L6 membrane proteins--a new four-transmembrane superfamily.

Authors:  M D Wright; J Ni; G B Rudy
Journal:  Protein Sci       Date:  2000-08       Impact factor: 6.725

Review 2.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

3.  TM4SF1: a new vascular therapeutic target in cancer.

Authors:  Chi-Iou Lin; Anne Merley; Tracey E Sciuto; Dan Li; Ann M Dvorak; Juan M Melero-Martin; Harold F Dvorak; Shou-Ching S Jaminet
Journal:  Angiogenesis       Date:  2014-07-02       Impact factor: 9.596

4.  Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue.

Authors:  E Lavie; D L Hirschberg; G Schreiber; K Thor; L Hill; I Hellstrom; K E Hellstrom
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Cloning and expression of the tumor-associated antigen L6.

Authors:  J S Marken; G L Schieven; I Hellström; K E Hellström; A Aruffo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

6.  Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.

Authors:  F Buchegger; C Pfister; K Fournier; F Prevel; M Schreyer; S Carrel; J P Mach
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

7.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

Authors:  M Q Xia; G Hale; M R Lifely; M A Ferguson; D Campbell; L Packman; H Waldmann
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

8.  Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling.

Authors:  Hua Gao; Goutam Chakraborty; Zhanguo Zhang; Intissar Akalay; Mayur Gadiya; Yaquan Gao; Surajit Sinha; Jian Hu; Cizhong Jiang; Muzaffar Akram; Edi Brogi; Birgit Leitinger; Filippo G Giancotti
Journal:  Cell       Date:  2016-06-30       Impact factor: 41.582

9.  Nanopodia--thin, fragile membrane projections with roles in cell movement and intercellular interactions.

Authors:  Chi-Iou Lin; Chun-Yee Lau; Dan Li; Shou-Ching Jaminet
Journal:  J Vis Exp       Date:  2014-04-03       Impact factor: 1.355

10.  Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer.

Authors:  G E Goodman; I Hellstrom; D E Yelton; J L Murray; S O'Hara; E Meaker; L Zeigler; P Palazollo; C Nicaise; J Usakewicz
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.